AZ Makes Fresh mRNA Move With Ethris Respiratory Pact
Executive Summary
A long-time player in messenger RNA through its partnership with Moderna Therapeutics, AstraZeneca has paid €25m upfront to a German biotech to find targets for investigation in asthma, COPD and idiopathic pulmonary fibrosis.
You may also be interested in...
J.P. Morgan Notebook Day 4: CRISPR's Not Worried; Theratechnologies' HIV Niche; And Is Moderna's IPO Coming Soon?
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference: Alder's Options for CGRP drug; CRISPR's not worried about Cas9 controversy; Theratechnologies seeks more HIV niche products; Moderna is shaping up to have a big 2018; TG Therapeutics and Immunomedics milestones ahead.
J.P. Morgan Notebook Day 4: CRISPR's Not Worried; Theratechnologies' HIV Niche; And Is Moderna's IPO Coming Soon?
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference: Alder's Options for CGRP drug; CRISPR's not worried about Cas9 controversy; Theratechnologies seeks more HIV niche products; Moderna is shaping up to have a big 2018; TG Therapeutics and Immunomedics milestones ahead.
End Of The Line For AstraZeneca’s Tralokinumab In Asthma
Another Phase III failure looks likely to spell the end for AstraZeneca’s tralokinumab in severe uncontrolled asthma. The company’s eyes are now firmly fixed on benralizumab.